Zhejiang pharma group selling probiotics, plant-based drugs and other OTC and prescription health products.
Zhejiang pharma group selling probiotics, plant-based drugs and other OTC and prescription health products.
In one line: A diversified Chinese Bayer Consumer Health.
Moat: narrow (brand, distribution). Established OTC and probiotic brands with broad pharmacy distribution across China.
Headquarters: Hangzhou, China · Employees: 7,826
Size Zhejiang CONBA Pharmaceutical (600572.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.52B, the 1497th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.15 on 18 Nov 2026.
Performance Over six months the shares fell 3.7%, against -14.5% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue grew 4.1% over the last twelve months (peer median +3.6%); the operating margin is 9.4% (peer median 10.4%).
Valuation It trades at 16.0× forward earnings against a peer median of 28.1× (4th cheapest of 13).
Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -8 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.4 points above its cost of capital (5.4% WACC).
Next results Next results expected around 16 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥6.83B | CN¥6.42B | CN¥6.44B | CN¥6.65B | CN¥5.93B |
| Revenue growth | — | 0% | -3% | +12% | — |
| Gross profit | CN¥3.93B | CN¥3.27B | CN¥3.27B | CN¥3.72B | CN¥3.37B |
| EBITDA | n/a | CN¥858M | CN¥907M | CN¥1.01B | CN¥966M |
| Net income | CN¥457M | CN¥474M | CN¥622M | CN¥592M | CN¥358M |
| Free cash flow | CN¥1.04B | CN¥830M | CN¥754M | CN¥712M | CN¥892M |
| Capital expenditure | CN¥224M | CN¥147M | CN¥291M | CN¥209M | CN¥292M |
| Total debt | CN¥354M | CN¥506M | CN¥625M | CN¥1.36B | CN¥1.23B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Zhejiang CONBA Pharmaceutical 600572.SS | $1.52B | -4% | +4% | 9% | 16.0× | -6.1% |
| By-health 300146.SZ | $2.56B | -1% | +10% | 11% | 24.7× | 4.8% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% |
| Yunnan Baiyao 000538.SZ | $15.0B | +11% | +5% | 11% | 18.3× | -0.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600572.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.7% | -5.8% | 9th highest of 21 |
| 6-month return | -3.7% | -14.5% | 8th highest of 21 |
| Distance from 52-week high | -19.7% | -40.5% | 6th highest of 21 |
| Revenue growth (TTM) | +4.1% | +3.6% | 11th highest of 21 |
| Operating margin | 9.4% | 10.4% | 10th lowest of 21 |
| Forward P/E | 16.0× | 28.1× | 4th cheapest of 13 |
| Growth the price implies (Req g, 7 yrs) | -6.1% | 9.4% | 5th least demanding of 13 |
| Growth delivered (Del g) | +1.9% | +4.0% | 7th highest of 13 |
| Hurdle (Req g minus delivered) | -8.0 pp | +12.4 pp | 4th least demanding of 13 |
| ROIC minus cost of capital | +4.4 pp | -1.3 pp | 7th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.52B | -4% | +4% | 9% | 16.0× | -6.1% | +1.9% |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.52B | -9% | +16% | 24% | n/a | -4.9% | +0.2% |
| ABL Bio 298380.KS | South Korea | $1.51B | -71% | -53% | -201% | n/a | n/a | n/a |
| Sarepta Therapeutics SRPT | United States | $1.56B | -15% | -19% | 0% | n/a | -6.8% | +32.4% |
| LigaChem Biosciences 141080.KS | South Korea | $1.48B | -72% | -55% | -324% | n/a | n/a | n/a |
| Corona Remedies CORONA.NS | India | $1.48B | +27% | +17% | 18% | 58.9× | 36.3% | +16.6% |
| Yifan Pharmaceutical 002019.SZ | China | $1.57B | -19% | -5% | 8% | 25.6× | n/a | n/a |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.59B | 0% | -4% | 15% | 47.2× | 6.0% | -4.3% |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.59B | -8% | +18% | 7% | 29.0× | n/a | n/a |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.59B | -14% | -13% | 6% | 12.6× | -6.6% | -5.6% |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.60B | -31% | -13% | 12% | 57.4× | 12.8% | -14.0% |
| Sino Biological 301047.SZ | China | $1.60B | +27% | +20% | 17% | 51.6× | 31.1% | -15.1% |
| Xiamen Kingdomway 002626.SZ | China | $1.45B | -3% | -3% | 11% | 27.2× | n/a | n/a |
| Anupam Rasayan India ANURAS.NS | India | $1.61B | -3% | +24% | 16% | 49.9× | n/a | n/a |
| Phibro Animal Health PAHC | United States | $1.44B | +5% | +10% | 13% | 9.9× | -6.4% | +12.7% |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.62B | -30% | +30% | 10% | n/a | 42.4% | +23.0% |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $1.62B | -47% | -18% | 9% | n/a | 33.0% | +0.9% |
| Mezzion Pharma 140410.KS | South Korea | $1.43B | -15% | +13% | -211% | n/a | n/a | n/a |
| Voronoi 310210.KS | South Korea | $1.43B | -62% | -100% | -438,152% | n/a | n/a | n/a |
| Marksans Pharma MARKSANS.NS | India | $1.43B | +36% | +24% | 20% | 23.2× | 31.0% | +16.6% |
| Nippon Shinyaku 4516.T | Japan | $1.42B | -20% | +18% | 18% | 7.9× | -18.1% | +7.0% |